Atlas FDA

cobas® KRAS Mutation Test

FDA premarket approval P140023/S024 · decided 2022-11-29

Approval details

PMA number
P140023
Supplement
S024
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
cobas® KRAS Mutation Test
Applicant
Roche Molecular Systems, Inc.
Date received
2022-10-18
Decision date
2022-11-29
Days to decision
42 days
Decision code
OK30
Advisory committee
Pathology
Expedited review
No
Location
Pleasanton, CA
Statement
Discontinuation of redundant pH testing for vialed Paraffin Binding Buffer.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
cobas® BV/CV (K260021)Roche Molecular Systems, Inc.2026-07-16
cobas CT/NG for use on the cobas 5800/6800/8800 systems; cobas TV/MG for use on the cobas 5800/6800/8800 systems (K260917)Roche Molecular Systems, Inc.2026-07-08
cobas liat CT/NG/MG nucleic acid test (K253759)Roche Molecular Systems, Inc.2026-05-15
cobas liat CT/NG nucleic acid test (K253756)Roche Molecular Systems, Inc.2026-05-15
cobas liat Bordetella panel nucleic acid test (K243753)Roche Molecular Systems, Inc.2025-11-20
cobas CMV (K252481)Roche Molecular Systems, Inc.2025-11-03
cobas HCV (K252484)Roche Molecular Systems, Inc.2025-11-03
cobas Respiratory 4-flex for use on the cobas 5800/6800/8800 Systems (K243455)Roche Molecular Systems, Inc.2025-07-31